Partners John Eliason and Mike Crossen were quoted in an American Banker article, “Banks explore ways to capitalize on tax law’s ‘Opportunity Zones,’” about potential business opportunities created by Opportunity Zones, an element of the federal tax cut law enacted in December 2017 that provides a way for private investors to receive tax benefits in exchange for investing in low- and moderate-income communities.
Eliason, who advises banks and private investors on tax issues, said such zones are fertile ground for private investment. “There is an estimated $6 trillion in investment opportunities that could be unlocked from this program,” he said.
Crossen, who has a public policy and transaction practice, said he takes the view that commercial and industrial loans will be eligible for the Opportunity Zones tax benefit. “If it ends up being only real estate, it will be a lost opportunity,” he said.
Eliason, who advises banks and private investors on tax issues, said such zones are fertile ground for private investment. “There is an estimated $6 trillion in investment opportunities that could be unlocked from this program,” he said.
Crossen, who has a public policy and transaction practice, said he takes the view that commercial and industrial loans will be eligible for the Opportunity Zones tax benefit. “If it ends up being only real estate, it will be a lost opportunity,” he said.
Related News
08 May 2024
In the News
Benjamin Dryden on Noncompete Ban – Expect Trade Secret Litigation Increase in ‘Volume and Nastiness’
Foley & Lardner LLP partner Benjamin Dryden offered insight on the specific impact to the manufacturing sector of the U.S. Federal Trade Commission’s (FTC) recently issued final rule banning noncompete agreements
08 May 2024
In the News
Foley Real Estate, Hospitality Transactions Highlighted in Golf Inc.
Foley & Lardner LLP served as legal advisor on two of Golf Inc.’s Top 10 Sales of 2023.
08 May 2024
In the News
Kyle Faget Assesses FDA Rule Regulating Lab-Developed Tests, Potential Challenges
Foley & Lardner LLP partner Kyle Faget offers insight on potential challenges to the U.S. Food and Drug Administration’s (FDA) final rule regulating lab-developed tests (LDTs)